Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Outstanding (Weighted Average): 2020-2025

Historic Shares Outstanding (Weighted Average) for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Sep 2025 value amounting to $119.9 million.

  • Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) rose 2.58% to $119.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.9 million, marking a year-over-year increase of 2.58%. This contributed to the annual value of $118.6 million for FY2024, which is 25.70% up from last year.
  • Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) amounted to $119.9 million in Q3 2025, which was up 0.59% from $119.2 million recorded in Q2 2025.
  • In the past 5 years, Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) ranged from a high of $119.9 million in Q3 2025 and a low of $50.1 million during Q1 2021.
  • For the 3-year period, Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) averaged around $98.6 million, with its median value being $115.8 million (2024).
  • Data for Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) shows a peak YoY surged of 89.59% (in 2024) over the last 5 years.
  • Over the past 5 years, Arcutis Biotherapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $50.3 million in 2021, then grew by 21.14% to $60.9 million in 2022, then skyrocketed by 54.91% to $94.4 million in 2023, then increased by 25.70% to $118.6 million in 2024, then climbed by 2.58% to $119.9 million in 2025.
  • Its last three reported values are $119.9 million in Q3 2025, $119.2 million for Q2 2025, and $118.6 million during Q1 2025.